{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:59:33Z","timestamp":1792828773908,"version":"4.5.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In the past few decades, PET with <jats:sup>18<\/jats:sup>F-FDG has been used for the diagnosis of gynecological malignancies and is considered to be superior to conventional imaging methods in diagnostic accuracy for detecting metastatic lesions and local recurrence and in evaluating the treatment response. On the other hand, several gynecological tumors, such as endometrial cancer and leiomyoma, and breast cancer are estrogen-dependent, in which estrogen is essential for their development and progression. <jats:sup>18<\/jats:sup>F-FES is an <jats:sup>18<\/jats:sup>F-labeled compound of estradiol, the most bioactive type of estrogen, and <jats:sup>18<\/jats:sup>F-FES PET has been well-established for diagnosis, staging, and posttherapeutic follow-up in patients with estrogen receptor\u2013positive breast cancer. Compared with in vitro assessment of tumor biopsy material, PET imaging has the advantages of being able to measure in vivo tumor behavior, characterize the entire tumor burden, and capture the heterogeneity of the tumor phenotype. In this article, we review the phenotyping of estrogen-related gynecological tumors other than breast cancer using <jats:sup>18<\/jats:sup>F-FES PET and demonstrate the additional value of <jats:sup>18<\/jats:sup>F-FES PET to <jats:sup>18<\/jats:sup>F-FDG PET in their diagnosis and prognostication. Moreover, promising PET tracers other than <jats:sup>18<\/jats:sup>F-FES and <jats:sup>18<\/jats:sup>F-FDG for the evaluation of estrogen-related gynecological tumors are introduced.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004258","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T16:01:53Z","timestamp":1654704113000},"page":"e481-e488","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["PET Imaging of Estrogen Receptors for Gynecological Tumors"],"prefix":"10.1097","volume":"47","author":[{"given":"Tetsuya","family":"Tsujikawa","sequence":"first","affiliation":[{"name":"Biomedical Imaging Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Makino","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tsuyoshi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kiyono","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Okazawa","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semnuclmed.2007.08.004","article-title":"18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization","volume":"37","year":"2007","journal-title":"Semin Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.2174\/092986712801215919","article-title":"Positron emission tomography radiopharmaceuticals for sex steroid hormone receptor imaging","volume":"19","year":"2012","journal-title":"Curr Med Chem"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2214\/ajr.182.1.1820227","article-title":"Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer","volume":"182","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"bib4-20250621","first-page":"1842","article-title":"Oncologic imaging in gynecologic malignancies","volume":"46","year":"2005","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00259-005-1876-y","article-title":"18F-FDG PET in the management of endometrial cancer","volume":"33","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCO.0b013e32832ec63f","article-title":"Role of PET in gynecologic malignancy","volume":"21","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/14737140.9.1.75","article-title":"PET and PET-CT imaging of gynecological malignancies: present role and future promise","volume":"9","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1677\/joe.0.1630379","article-title":"Estrogen receptor beta\u2014a new dimension in estrogen mechanism of action","volume":"163","year":"1999","journal-title":"J Endocrinol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/bbrc.1997.7893","article-title":"The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro","volume":"243","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2016.08.008","article-title":"Endocrine treatment in breast cancer: cure, resistance and beyond","volume":"50","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","year":"2009","journal-title":"Gynecol Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.1996.0273","article-title":"Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival","volume":"63","year":"1996","journal-title":"Gynecol Oncol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study","volume":"106","year":"2007","journal-title":"Gynecol Oncol"},{"key":"bib14-20250621","first-page":"1212","article-title":"Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats","volume":"25","year":"1984","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1021\/jm050121f","article-title":"Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol","volume":"48","year":"2005","journal-title":"J Med Chem"},{"key":"bib16-20250621","first-page":"1526","article-title":"Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma","volume":"32","year":"1991","journal-title":"J Nucl Med"},{"key":"bib17-20250621","first-page":"1766","article-title":"Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays","volume":"36","year":"1995","journal-title":"J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002590050359","article-title":"Positron emission tomographic assessment of \u201cmetabolic flare\u201d to predict response of metastatic breast cancer to antiestrogen therapy","volume":"26","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1200\/JCO.2005.04.3810","article-title":"Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nucmedbio.2005.11.002","article-title":"Automatic synthesis of 16\u03b1-[18F]fluoro-17\u03b2-estradiol using a cassette-type [18F]fluorodeoxyglucose synthesizer","volume":"33","year":"2006","journal-title":"Nucl Med Biol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0969-8051(97)00002-4","article-title":"Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES)","volume":"24","year":"1997","journal-title":"Nucl Med Biol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0969-8051(99)00072-4","article-title":"Interactions of 16\u03b1-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP)","volume":"26","year":"1999","journal-title":"Nucl Med Biol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nucmedbio.2006.12.003","article-title":"In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET\u2014influence of menstrual cycle and endogenous estrogen level","volume":"34","year":"2007","journal-title":"Nucl Med Biol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jcem-67-2-334","article-title":"Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle","volume":"67","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01606522","article-title":"Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy","volume":"419","year":"1991","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/jrf.0.0940363","article-title":"Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause","volume":"94","year":"1992","journal-title":"J Reprod Fertil"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0301-2115(00)00554-6","article-title":"Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle","volume":"98","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/humrep\/14.11.2844","article-title":"Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors a and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy","volume":"14","year":"1999","journal-title":"Hum Reprod"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/humrep\/14.1.190","article-title":"The cyclic pattern of the immunocytochemical expression of oestrogen and progesterone receptors in human myometrial and endometrial layers: characterization of the endometrial-subendometrial unit","volume":"14","year":"1999","journal-title":"Hum Reprod"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsgi.2003.09.003","article-title":"Expression of nuclear receptors and cofactors in human endometrium and myometrium","volume":"11","year":"2004","journal-title":"J Soc Gynecol Investig"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9378(80)91018-2","article-title":"Estradiol and progesterone receptors in human endometrium: normal and abnormal menstrual cycles and early pregnancy","volume":"136","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1148\/radiol.2482071379","article-title":"Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET\u2014initial experience","volume":"248","year":"2008","journal-title":"Radiology"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.108.060145","article-title":"Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00259-010-1589-8","article-title":"Functional oestrogen receptor \u03b1 imaging in endometrial carcinoma using 16\u03b1-[18F]fluoro-17\u03b2-oestradiol PET","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0969-8051(93)90160-V","article-title":"Titration of the in vivo uptake of 16\u03b1-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development","volume":"20","year":"1993","journal-title":"Nucl Med Biol"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/1097-0142(20000815)89:4<800::AID-CNCR12>3.0.CO;2-Y","article-title":"Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study","volume":"89","year":"2000","journal-title":"Cancer"},{"key":"bib38-20250621","first-page":"258","article-title":"Effects of tamoxifen on the human female genital tract: review of the literature","volume":"24","year":"2003","journal-title":"Eur J Gynaecol Oncol"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1102\/1470-7330.2008.0020","article-title":"The effect of tamoxifen on the genital tract","volume":"8","year":"2008","journal-title":"Cancer Imaging"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12149-007-0075-2","article-title":"Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia","volume":"22","year":"2008","journal-title":"Ann Nucl Med"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ygyno.2006.10.024","article-title":"The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer","volume":"104","year":"2007","journal-title":"Gynecol Oncol"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000002612","article-title":"Predictive value of 16\u03b1-[18F]-Fluoro-17\u03b2-estradiol PET as a biomarker of progestin therapy resistance in patients with atypical endometrial hyperplasia and low-grade endometrial cancer","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2967\/jnumed.120.244319","article-title":"Prognostic value of 16\u03b1-18F-Fluoro-17\u03b2-estradiol PET as a predictor of disease outcome in endometrial cancer: a prospective study","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2214\/AJR.09.4074","article-title":"Spectrum of FDG PET\/CT findings of uterine tumors","volume":"195","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"bib46-20250621","first-page":"709","article-title":"Estrogen and progesterone receptors in uterine sarcomas","volume":"68","year":"1986","journal-title":"Obstet Gynecol"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-011-1851-8","article-title":"Additional value of 16\u03b1-[18F]fluoro-17\u03b2-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1097\/RLU.0000000000001678","article-title":"A novel diagnostic strategy using 16\u03b1-[18F]-Fluoro-17-\u03b2-estradiol (18F-FES) PET\/MRI to achieve complete resection of intravenous leiomyomatosis in reproductive-age women","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2967\/jnumed.112.113472","article-title":"18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib50-20250621","doi-asserted-by":"crossref","first-page":"22581","DOI":"10.18632\/oncotarget.15127","article-title":"18F-FDG\/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1757-2215-2-7","article-title":"Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16\u03b1-18F-fluoro-17\u03b2-estradiol PET","volume":"2","year":"2009","journal-title":"J Ovarian Res"},{"key":"bib52-20250621","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","article-title":"Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1002\/cam4.1741","article-title":"Role of tumor microenvironment in the pathobiology of ovarian cancer: insights and therapeutic opportunities","volume":"7","year":"2018","journal-title":"Cancer Med"},{"key":"bib54-20250621","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib57-20250621","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1007\/s00259-021-05378-0","article-title":"68Ga-FAPI-PET\/CT in patients with various gynecological malignancies","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib59-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RLU.0000000000003968","article-title":"Uterine uptake of 68Ga-FAPI-04 in uterine pathology and physiology","volume":"47","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:00:53Z","timestamp":1750536053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004258","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}